Emerging perspectives on lipid management: International approaches and global challenges

American Journal of Cardiology

Volumn 88, Issue 8, 2001, Pages 876-881

  Gotto Jr , Antonio M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DATA BASE; DECISION MAKING; DYSLIPIDEMIA; EUROPE; EVALUATION; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; TREATMENT OUTCOME; UNITED STATES;

EID: 0035887168     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(01)01895-1     Document Type: Note

References (32)

1. Maximizing the cost-effectiveness of lipid-lowering therapy
2. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
3. Secondary prevention by raising hdl cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study
4. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials
5. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity
6. Molecular bases of the acute coronary syndromes
7. Low-density lipoprotein-independent effects of statins
8. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
9. Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation
10. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
11. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
12. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
13. Long-term effects of pravastatin on plasma concentration of C-reactive protein
14. Lipoprotein associated phospholipase A2 as an independent predictor of coronary heart disease
15. Effects of atorvastatin on early recurrent events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
16. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types
17. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study
18. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
19. HMG-CoA reductase inhibitors and the risk of fractures
20. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
21. Statins and the risk of dementia
22. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
23. The National Cholesterol Education Program: Progress and prospects
24. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III)
25. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
26. Prediction of coronary heart disease using risk factor categories
27. Management of dyslipidemia in adults with diabetes
28. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
29. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study
30. Treatment of hyperlipidemia
31. Lifestyle and risk factor management and use of of drug therapies incoronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme
32. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals